Loading...
| A02681 | Pages: 130 | Jan 2021 | 5688 Views | | |
| Author(s) : Vishal Bhardwaj | Tables: 46 | Charts: 29 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Inhaled Nitric Oxide Market
Request Now !The global inhaled nitric oxide market size was valued at $634.4 million in 2019 and is estimated to reach $1,180.98 million by 2027, registering a CAGR of 8.1% from 2020 to 2027.
Inhaled nitric oxide has antiviral properties and improved oxygenation. Therefore, nitric oxide is now being tested as an experimental treatment for COVID-19. It is helpful in protecting healthcare workers on the front line of the pandemic from getting sick. Further, iNO is used for the treatment of pulmonary hypertension, ARDS, and other respiratory diseases, whereas several undergoing randomized clinical trials are being conducted to investigate the role of inhaled nitric oxide in COVID-19. Moreover, key players such as Mallinckrodt have also initiated a retrospective study for the use of iNO in COVID-19 patients. Moreover, multiple ongoing clinical trials are conducted for iNO as a treatment for COVID-19 and it is being used with promising results in the patient population.
Nitric oxide is a gas that is inhaled through the nose or mouth. It works by relaxing the smooth muscles to widen the blood vessels in the lungs. It is used together with a breathing machine (ventilator) and other agents to treat newborn (term and near-term) babies with respiratory failure that is caused by pulmonary hypertension.
Get more information on this report : Request Sample Pages
Nitric oxide is clinically efficient in dilating blood vessels and to relax muscle tension, which absorbs oxygen efficiently in the body. Furthermore, nitric oxide is usually used together with a breathing machine (ventilator). Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in a human was first described in the 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborn with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the U.S. first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
The major factors that contribute toward the growth of the market are increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). However, the rise in the number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) boost the growth of the inhaled nitric oxide market. However, the high cost of treatment and strict government regulations for various applications hamper the inhaled nitric oxide market growth.
Conversely, ongoing R&D activities leading to new application areas in the healthcare industry are expected to provide lucrative opportunities for the expansion of the global inhaled nitric oxide market in the near future.
The World Health Organization (WHO) on January 30, 2020, declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe.
Inhaled nitric oxide has antiviral property and improved oxygenation; therefore, nitric oxide is now being tested as an experimental treatment for COVID-19. It is also helpful in protecting healthcare workers on the front line of the pandemic from getting sick. Further, iNO is used for the treatment of pulmonary hypertension, ARDS, and other respiratory diseases, whereas several undergoing randomized clinical trials are being conducted to investigate the role of inhaled nitric oxide in COVID-19. Moreover, key players such as Mallinckrodt have also initiated a retrospective study for the use of iNO in COVID-19 patients. Moreover, multiple ongoing clinical trials are conducted for iNO as a treatment for COVID-19 and it is being used with promising results in the patient population.
In March, the U.S. FDA gave a handful of pharmaceutical company’s emergency clearance to allow the use of their nitric oxide devices to treat these patients, including Bellerophon Therapeutics and Vero Biotech. In addition, inhaled gas can have therapeutic benefits in COVID-19 patients by preventing further damage to the vessels inside the lungs.
The inhaled nitric oxide market is segmented on the basis of application and region. By application, the market is divided into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others (tuberculosis treatment). Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and Rest of World.
Presently, on the basis of application, the market is divided into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others (tuberculosis treatment).
Neonatal respiratory treatment is the major revenue contributor, and is projected to grow significantly during the forecast period. This is attributed to the increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF).
Get more information on this report : Request Sample Pages
Asia-Pacific is expected to be a growing region shortly on account of the number of highest live birth per 1000 people and the rise in prevalence of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN). The competitive market formed due to the emergence of local providers of nitric oxide therapy systems contributes toward the growth of the Asia- Pacific market.
The key players profiled in this report include Air Liquide S.A, Bellerophon Therapeutics, Inc., BOC Healthcare, Beyond Air, Inc, Halma Plc, Linde Plc, Mallinckrodt plc, Novoteris, LLC, VERO Biotech LLC, and Nu-Med Plus.
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.1.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five forces analysis
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Increase in demand from healthcare sector
3.5.1.2.Increase in chronic diseases
3.5.2.Restraints
3.5.2.1.High cost of treatment
3.5.2.2.Strict application norms
3.5.3.Opportunity
3.5.3.1.Ongoing R&D activities leading to new application areas in healthcare industry
3.6.Impact Analysis of COVID-19 on inhaled nitric oxide market
3.7.Inhaled nitric oxide concentrations
3.8.Clinical Trials – From 2010 to 2022
CHAPTER 4:INHALED NITRIC OXIDE MARKET, BY APPLICATION
4.1.Overview
4.1.1.Market size and forecast, by product
4.2.Neonatal respiratory treatment
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Chronic obstructive pulmonary disease (COPD)
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Acute respiratory distress syndrome (ARDS)
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Others
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:INHALED NITRIC OXIDE MARKET, BY REGION
5.1.Overview
5.1.1.Market size and forecast
5.2.North America
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.North America market size and forecast, by country
5.2.2.1.U.S.
5.2.2.1.1.U.S. market size and forecast, by application
5.2.2.2.Canada
5.2.2.2.1.Canada market size and forecast, by application
5.2.2.3.Mexico
5.2.2.3.1.Mexico market size and forecast, by application
5.2.3.North America market size and forecast, by application
5.3.Europe
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Europe inhaled nitric oxide market, by country
5.3.2.1.Germany
5.3.2.1.1.Germany market size and forecast, by application
5.3.2.2.France
5.3.2.2.1.France market size and forecast, by application
5.3.2.3.UK
5.3.2.3.1.UK market size and forecast, by application
5.3.2.4.Italy
5.3.2.4.1.Italy market size and forecast, by application
5.3.2.5.Rest of Europe
5.3.2.5.1.Rest of Europe market size and forecast, by application
5.3.3.Europe market size and forecast, by application
5.4.Asia-Pacific
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Asia-Pacific market size and forecast, by country
5.4.2.1.Japan
5.4.2.1.1.Japan market size and forecast, by application
5.4.2.2.Australia
5.4.2.2.1.Australia market size and forecast, by application
5.4.2.3.Rest of world
5.4.2.3.1.Rest of world market size and forecast, by application
5.4.3.Asia-Pacific market size and forecast, by application
CHAPTER 6:COMPANY PROFILES
6.1.AIR LIQUIDE S.A.
6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Operating business segments
6.1.4.Product Portfolio
6.1.5.Business performance
6.2.BELLEROPHON THERAPEUTICS, INC.
6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Product portfolio
6.2.4.Key strategic moves and developments
6.3.BOC HEALTHCARE
6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Product portfolio
6.4.BEYOND AIR, INC.
6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Product Portfolio
6.4.4.Business performance
6.4.5.Key strategic moves and developments
6.5.HALMA PLC
6.5.1.Company overview
6.5.2.Company snapshot
6.5.3.Operating business segments
6.5.4.Product portfolio
6.5.5.Business performance
6.6.LINDE PLC (PRAXAIR, INC.)
6.6.1.Company overview
6.6.2.Company snapshot
6.6.3.Product Portfolio
6.6.4.Business performance
6.6.5.Key strategic moves and developments
6.7.MALLINCKRODT PLC
6.7.1.Company overview
6.7.2.Company snapshot
6.7.3.Operating business segments
6.7.4.Product portfolio
6.7.5.Business performance
6.7.6.Key strategic moves and developments
6.8.NOVOTERIS, LLC
6.8.1.Company overview
6.8.2.Company snapshot
6.8.3.Product Portfolio
6.9.VERO BIOTECH LLC
6.9.1.Company overview
6.9.2.Company snapshot
6.9.3.Product portfolio
6.9.4.Key strategic moves and developments
6.10.NU-MED PLUS
6.10.1.Company overview
6.10.2.Company snapshot
6.10.3.Operating business segments
6.10.4.Product Portfolio
LIST OF TABLES
TABLE 01.GLOBAL INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 02.INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, BY REGION, 2019-2027 ($MILLION)
TABLE 03.INHALED NITRIC OXIDE MARKET FOR COPD, BY REGION, 2019-2027 ($MILLION)
TABLE 04.INHALED NITRIC OXIDE MARKET FOR ARDS, BY REGION, 2019-2027 ($MILLION)
TABLE 05.INHALED NITRIC OXIDE MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
TABLE 06.INHALED NITRIC OXIDE MARKET, BY REGION, 2019–2027($MILLION)
TABLE 07.NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 08.U.S. INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 09.CANADA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 10.MEXICO INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 11.NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 12.EUROPE INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 13.GERMANY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 14.FRANCE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 15.UK INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 16.ITALY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 17.REST OF EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 18.EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 19.ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2019–2027($MILLION)
TABLE 20.JAPAN INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 21.AUSTRALIA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 22.REST OF WORLD INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 23.ASIA-PACIFIC AND REST OF WORLD INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2019–2027($MILLION)
TABLE 24.AIR LIQUIDE: COMPANY SNAPSHOT
TABLE 25.AIR LIQUIDE: OPERATING SEGMENT
TABLE 26.AIR LIQUIDE: PRODUCT PORTFOLIO
TABLE 27.BELLEROPHON THERAPEUTICS: COMPANY SNAPSHOT
TABLE 28.BELLEROPHON THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 29.BOC HEALTHCARE: COMPANY SNAPSHOT
TABLE 30.BOC HEALTHCARE: PRODUCT PORTFOLIO
TABLE 31.BEYOND AIR: COMPANY SNAPSHOT
TABLE 32.BEYOND AIR: PRODUCT PORTFOLIO
TABLE 33.HALMA: COMPANY SNAPSHOT
TABLE 34.HALMA: BUSINESS SEGMENTS
TABLE 35.HALMA: PRODUCT PORTFOLIO
TABLE 36.LINDE: COMPANY SNAPSHOT
TABLE 37.LINDE: PRODUCT PORTFOLIO
TABLE 38.MALLINCKRODT: COMPANY SNAPSHOT
TABLE 39.MALLINCKRODT: BUSINESS SEGMENTS
TABLE 40.MALLINCKRODT: PRODUCT PORTFOLIO
TABLE 41.NOVOTERIS: SNAPSHOT
TABLE 42.NOVOTERIS: PRODUCT PORTFOLIO
TABLE 43.VERO BIOTECH: COMPANY SNAPSHOT
TABLE 44.VERO BIOTECH: PRODUCT PORTFOLIO
TABLE 45.NU-MED PLUS: COMPANY SNAPSHOT
TABLE 46.NU-MED PLUS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.INHALED NITRIC OXIDE MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019–2020*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2020* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019–2020*
FIGURE 06.TOP PLAYER POSITIONING
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.LOW THREAT OF SUBSTITUTION
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 13.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR COPD, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR ARDS , 2019 & 2027 (%)
FIGURE 16.COMPARATIVE COUNTRY ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR OTHERS , 2019 & 2027 (%)
FIGURE 17.AIR LIQUIDE: NET SALES, 2017–2019 ($MILLION)
FIGURE 18.AIR LIQUIDE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 19.AIR LIQUIDE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 20.BEYOND AIR: NET SALES, 2019-2020 ($MILLION)
FIGURE 21.HALMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.HALMA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23.HALMA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 24.LINDE: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.LINDE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 26.LINDE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 27.MALLINCKRODT: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.MALLINCKRODT: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 29.MALLINCKRODT: REVENUE SHARE BY REGION, 2019 (%)
According to analyst perspective, the global inhaled nitric oxide market is driven by factors such as increase in the prevalence of respiratory treatment in neonates has resulted in increased use of inhaled nitric oxide therapy and an increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF) that affects 2% of all live births and is responsible for >33% of all neonatal mortality in the U.S. increased the demand for the growth of inhaled nitric oxide market. Further, the use of inhaled nitric oxide helps the patients with acute respiratory failure, potentially improving oxygenation, and lowering pulmonary vascular resistance disease.
In addition, key players in this industry have focused on the effective therapy due to its antibacterial and oxygenation activity which boosts the market growth. This also leads to an increase in R&D activities and improves inhaled nitric oxide applications across the globe.
A. The total market value of inhaled nitric oxide market is $634.4 million in 2019.
A. The forcast period for inhaled nitric oxide market is 2020 to 2027.
A. The market value of inhaled nitric oxide market in 2027 is $1180.98 million.
A. The base year is 2019 in inhaled nitric oxide market.
A. Linde Plc, Mallinckrodt plc, Novoteris, LLC, VERO Biotech LLC, held a high market postion owing to the strong geographical foothold in different regions.
A. Neonatal respiratory treatment, segment is the major revenue contributor, and is projected to grow significantly during the forecast period. This is attributed to the increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF).
A. "The major factors that contribute toward the growth of the market are increase in the prevalence of diseases in the newborn such as persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). However, the rise in the number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) boost the growth of the inhaled nitric oxide market. "
A. Increase in number of highest live birth per 1000 people and the rise in prevalence of respiratory distress syndrome, neonatal jaundice, and hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN).
A. Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays a major role in regulating vascular muscle tone. It has emerged as a treatment for hypoxemic respiratory failure in newly born infants that is associated with persistent pulmonary hypertension of the newborn.
A. Inhaled nitric oxide market is used together with a breathing machine (ventilator) and other agents to treat newborn (term and near-term) babies with respiratory failure that is caused by pulmonary hypertension.
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
